The Project to End Post Partum Breast Cancer
Many people are unfamiliar with Postpartum Breast Cancer (PPBC), a little-known subset of breast cancer that occurs in women within 10 years of childbirth. This episode of our podcast delves into this personal topic for several members of our team.
Drs. Virginia Borges and Pepper Schedin are launching the first-ever clinical trial to prevent PPBC. Their groundbreaking approach involves giving healthy new mothers a brief course of ibuprofen as they wean their babies from breastfeeding. This trial holds huge potential for global impact, and the doctors need the public’s help to make it happen.
MBC 101: Tumor Microenvironment with Dr. Amy Beumer
Have you ever wondered how our cancer metastasizes? Why is it that some treatments just don’t work? Can we as patients living with MBC alter cellular level activity? In this episode, you will hear the answers to these questions and more. Join us as we take a step back to the basics of tumor microenvironment with our guest, Dr. Amy Beumer, who will break down the science into smaller, digestible bites. In this lively discussion, Dr. Amy explains the how and the why of this tough topic. You will hear her say “This is fun” and use engaging, relatable metaphors like “Picture your neighborhood and that one neighbor…..” By the end, I assure you that you’ll walk away with a deeper understanding of tumor microenvironment than when you started.
Pull up a chair, listen in your car, or on your daily walk, we are with you wherever you listen to your podcasts. Terms and other resources are provided in the episode notes.
Protecting Our Loved Ones at Risk
Many with metastatic breast cancer fear for their children and siblings: How can we help them avoid the same diagnosis? Are there ways to minimize risk?
In this episode, host Martha Carlson speaks with her eldest child, who’s navigating personal and family risk factors despite no known genetic predispositions. Join us for this powerful and informative episode where we interview Dr. Sagar Sardesai from Ohio State University’s High Risk Breast Clinic.